|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
21,110,000 |
Market
Cap: |
5.48(M) |
Last
Volume: |
4,769,812 |
Avg
Vol: |
4,756,851 |
52
Week Range: |
$0.2598 - $0.2598 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Plus Therapeutics is a clinical-stage pharmaceutical company focused on the development, manufacture and commercialization of treatments for patients battling cancer and other life-threatening diseases. The clinical stage drugs in Co.'s pipeline are: Rhenium NanoLiposomes, a radiotherapy for patients with recurrent glioblastoma; DocePLUS, a chemotherapy for patients with tumors that has been evaluated in a completed U.S. single-center Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy that has been evaluated in a completed, bioequivalence clinical trial in the U.S., Canada, and Ukraine versus Janssen's CAELYX® in patients with ovarian cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
48,285 |
48,285 |
99,872 |
108,373 |
Total Buy Value |
$98,501 |
$98,501 |
$181,784 |
$199,106 |
Total People Bought |
6 |
6 |
6 |
6 |
Total Buy Transactions |
6 |
6 |
16 |
20 |
Total Shares Sold |
0 |
0 |
2,068 |
3,568 |
Total Sell Value |
$0 |
$0 |
$4,053 |
$4,525 |
Total People Sold |
0 |
0 |
1 |
2 |
Total Sell Transactions |
0 |
0 |
1 |
2 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Rickey David |
Director |
|
2013-09-05 |
4 |
B |
$2.24 |
$4,480 |
I/I |
2,000 |
186,976 |
2.1 |
- |
|
Rickey David |
Director |
|
2013-09-04 |
4 |
OE |
$2.20 |
$26,125 |
I/I |
11,875 |
184,976 |
|
- |
|
Rickey David |
Director |
|
2013-09-03 |
4 |
B |
$2.13 |
$14,976 |
I/I |
7,000 |
173,101 |
2.1 |
- |
|
Thompson Tommy G |
Director |
|
2013-08-30 |
4 |
B |
$2.14 |
$10,700 |
D/D |
5,000 |
39,050 |
2.39 |
- |
|
Shirahama Norio Seijiro |
President - Asia Pacific |
|
2013-01-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,366) |
48,659 |
|
- |
|
Saad Mark E |
Chief Financial Officer |
|
2013-01-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(14,070) |
138,430 |
|
- |
|
Hedrick Marc H |
President |
|
2013-01-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(15,477) |
504,611 |
|
- |
|
Calhoun Christopher J |
Chief Executive Officer |
|
2013-01-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(21,105) |
147,270 |
|
- |
|
Holmes E Carmack |
Director |
|
2013-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,100 |
6,100 |
|
- |
|
Dean Lloyd H |
Director |
|
2013-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,100 |
6,100 |
|
- |
|
Hawran Paul W |
Director |
|
2013-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,100 |
6,100 |
|
- |
|
Rickey David |
Director |
|
2013-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,100 |
6,100 |
|
- |
|
Thompson Tommy G |
Director |
|
2013-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,100 |
6,100 |
|
- |
|
Hawkins Richard J |
Director |
|
2013-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,100 |
6,100 |
|
- |
|
Hedrick Marc H |
President |
|
2012-12-19 |
4 |
B |
$2.85 |
$28,500 |
I/I |
10,000 |
2,500 |
2.66 |
- |
|
Rickey David |
Director |
|
2012-12-19 |
4 |
B |
$2.85 |
$91,200 |
I/I |
32,000 |
158,101 |
2.1 |
- |
|
Dean Lloyd H |
Director |
|
2012-12-19 |
4 |
B |
$2.85 |
$71,250 |
I/I |
25,000 |
40,000 |
2.1 |
- |
|
Hedrick Marc H |
President |
|
2012-12-10 |
5 |
GD |
$0.00 |
$0 |
I/I |
3,200 |
9,600 |
|
- |
|
Saad Mark E |
Chief Financial Officer |
|
2012-03-14 |
4 |
B |
$2.54 |
$25,494 |
D/D |
10,000 |
152,500 |
2.74 |
- |
|
Shirahama Norio Seijiro |
President - Asia Pacific |
|
2012-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
51,825 |
62,025 |
|
- |
|
Shirahama Norio Seijiro |
President - Asia Pacific |
|
2012-01-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(31,825) |
10,200 |
|
- |
|
Hedrick Marc H |
President |
|
2012-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
61,850 |
510,088 |
|
- |
|
Hedrick Marc H |
President |
|
2012-01-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(36,850) |
448,238 |
|
- |
|
Calhoun Christopher J |
Chief Executive Officer |
|
2012-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
85,250 |
168,375 |
|
- |
|
Calhoun Christopher J |
Chief Executive Officer |
|
2012-01-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(50,250) |
83,125 |
|
- |
|
340 Records found
|
|
Page 6 of 14 |
|
|